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Background: We compared the time to discontinuation due to lack of tolerability over 24 weeks in patients
suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, the prodrug of
metabotropic glutamate 2/3 receptor agonist, LY404039) or standard of care (SOC: olanzapine, risperidone, or
aripiprazole).
Methods: Study HBBR was a multicenter, randomized, open-label study comparing the long-term safety and
tolerability of LY2140023 with SOC for schizophrenia. Patients had moderate symptomatology with prominent
negative symptoms and evidence of functional impairment. Those who met entry criteria were randomized to
open-label treatment with either LY2140023 (target dose: 40 mg twice daily [BID]; n = 130) or SOC (n = 131).
Results: There was no statistically significant difference between LY2140023 and SOC for time to discontinuation
due to lack of tolerability (primary objective; P = .184). The Kaplan-Meier estimates revealed comparable time to
event profiles. Only 27% of LY2140023 and 45% of SOC patients completed the 24-week open-label, active
treatment phase. Twenty-seven patients (20.8%) in the LY2140023 group and 15 patients (11.5%) in the SOC group
discontinued due to lack of efficacy (P = .044). Twenty-three patients (17.7%) in the LY2140023 group and 19
patients (14.5%) in the SOC group discontinued due to adverse events (physician and subject decision combined,
P = .505). The incidence of serious adverse events was comparable between groups. LY2140023-treated patients
reported significantly more treatment-emergent adverse events of vomiting, agitation, and dyspepsia, while SOC-
treated patients reported significantly more akathisia and weight gain. The incidence of treatment-emergent
parkinsonism (P = .011) and akathisia (P = .029) was significantly greater in SOC group. Improvement in PANSS total
score over the initial 6 to 8 weeks of treatment was similar between groups, but improvement was significantly
greater in the SOC group at 24-week endpoint (P = .004). LY2140023 and SOC groups had comparable negative
symptom improvement at 24-week endpoint (P = .444).
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Conclusion: These data provide further evidence that the potential antipsychotic LY2140023 monohydrate, with a
glutamatergic mechanism of action, may have a unique tolerability profile characterized by a low association with
some adverse events such as extrapyramidal symptoms and weight gain that may characterize currently available
dopaminergic antipsychotics.
Trials registration: A Long-term, Phase 2, Multicenter, Randomized, Open-label, Comparative Safety Study of
LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia
ClinicalTrials.gov identifier: NCT00845026.
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LY2140023 monohydrate (LY2140023) is an oral methio-
nine prodrug of LY404039, a potent and highly selective
agonist for the metabotropic glutamate receptors 2 and
3 (mGlu2/3) [1,2]. LY2140023 is undergoing testing in
clinical trials as a potential treatment for schizophrenia.
In a randomized, double-blind, placebo- and active-
controlled (olanzapine) clinical trial (HBBD) over a 4-week
treatment period, patients receiving 40 mg twice daily
(BID) of LY2140023 demonstrated statistically significant
improvements in the Positive and Negative Syndrome
Scale (PANSS) [3] total score compared with patients re-
ceiving placebo [4].
The efficacy results in a second, randomized, double-
blind, placebo- and active-controlled (olanzapine) clin-
ical trial (HBBI) lasting up to 4 weeks were inconclusive
[5]. None of the 4 LY2140023 doses (5 mg, 20 mg,
40 mg, or 80 mg BID) nor the olanzapine dose (15 mg
once daily) demonstrated changes different from placebo
in the PANSS total score, the primary measure of effi-
cacy. The heightened placebo response in the second
phase 2 study likely reduced the ability to detect a
significant drug response across the LY2140023 and
olanzapine treatment groups.
The safety results from both 4-week, Phase 2 clinical
trials comparing LY2140023 with placebo treatment
were generally similar. LY2140023 treatment was gener-
ally well-tolerated overall and not associated with eleva-
tions in prolactin, extrapyramidal symptoms, or weight.
However, in the HBBI study, convulsions were reported
in 4 patients treated with LY2140023 [5]. This latter
finding identified a potentially increased risk of seizures
during treatment with LY2140023, but further study is
needed to evaluate any potential relationship to duration
of exposure.
The current study (HBBR) is the first time patients
were assigned to long-term treatment with LY2140023.
It is important for assessing any potential association be-
tween prolonged duration of exposure to LY2140023
and the incidence of convulsions. The primary objective
of this study was to assess time to discontinuation dueto lack of tolerability among patients with schizophrenia
receiving LY2140023 versus those on atypical antipsychotic
standard of care (SOC) treatment for up to 24 weeks.
Methods
Study design
Study HBBR was a Phase 2, multicenter, randomized,
parallel, active-controlled study with an open-label de-
sign (Figure 1). Patients enrolled in this study were
male or female, 18 to 65 years of age (inclusive), with a
diagnosis of schizophrenia as defined in the Diagnostic
and Statistical Manual of Mental Disorders – Fourth
Edition – text revision (DSM-IV-TR) [6]. Diagnosis was
confirmed with the Structured Clinical Interview for
Diagnosis (SCID), performed by the principal investiga-
tor. Patients had at most moderate symptomatology, as
reflected by a score ≤4 (moderate) on the Clinical Global
Impressions-Severity (CGI-S) scale [7], with prominent
negative symptoms defined as symptom score ≥4 on at
least 3 items or a score ≥5 on at least 2 items of the
PANSS negative subscale [3], and evidence of functional
impairment at study entry. Assessment of “functional im-
pairment” was based on the clinical judgment of the prin-
cipal investigator. All investigators were trained that
functional impairment was a deficiency in the expected
tasks of patients as appropriate for a student, homemaker,
or worker. Patients were not eligible to participate in the
study if they had a history of seizures or additional speci-
fied criteria that indicated seizure tendency. All patients
gave written informed consent prior to entering the study.
The study protocol was approved by appropriate institu-
tional review boards and conducted in accordance with
the ethical principles stated in the Declaration of Helsinki.
This study was conducted from 2009 through 2010 at 29
centers in 4 countries; the number of patients in each
country were: Germany (n = 10, 3.8%), Mexico (n = 48,
18.4%), Russia (n = 86, 33.0%), and the United States
(n = 117, 44.8%).
The study included an up to 7-day antipsychotic drug
taper/discontinuation phase (Study Period I), a 3-day,
single-blind placebo lead-in phase (Study Period II), a
Figure 1 Study design. Abbreviations: AP = antipsychotic; ARI = aripiprazole; OLZ = olanzapine; LY = Lilly2140023; RIS = risperidone; SOC = standard of
care; vs. = versus. Dose range: LY2140023: 20, 40, or 80 mg, twice daily; ARI: 10, 20, or 30 mg, once daily; OLZ: 10, 15, or 20 mg, once daily; RIS: 2, 4, or
6 mg, once or twice daily.
Adams et al. BMC Psychiatry 2013, 13:143 Page 3 of 9
http://www.biomedcentral.com/1471-244X/13/14324-week open-label active treatment phase (Study Period
III), and an optional 28-week extension phase (Study
Period IV). All results pertain to Study Periods I through
III only. Patients were randomized to receive either
LY2140023 (20, 40, or 80 mg, BID; target dose = 40 mg
BID), or SOC (olanzapine [10, 15, or 20 mg, once daily;
target = 15 mg/day], aripiprazole [10, 20, or 30 mg, once
daily; target = 20 mg/day], or risperidone [2, 4, or 6 mg,
once or twice daily; target = 4 mg/day]) treatment. Doses
of comparators were based on U.S. labeling. Based upon
the available Phase 2 data, an optimal dose of LY2140023
had not yet been identified.
The treating clinician was free to select which SOC
antipsychotic to use for each patient randomly assigned
to SOC treatment; the clinician was not permitted to
switch a patient to another SOC medication once treat-
ment began. Patients randomized to receive LY2140023
were started at a dose of 40 mg BID. For patients ran-
domized to receive SOC treatment, investigators were
instructed to begin patients at doses below the target
dose for the first 3 days to minimize the potential for ad-
verse events. Dose adjustments, other than the initial
scheduled dose titration, were made only if investigators
had concerns about patient safety/tolerability or lack of
response. Dose decreases to accommodate investigator
concern about a patient’s safety or tolerability to study
medication could occur at any time, based on theinvestigator’s clinical judgment; only 1 dose decrease
was permitted between visits. Dose decreases for pa-
tients receiving LY2140023 should be from 80 mg/day to
40 mg/day (with no intermediate dose). Dose increases
to potentially improve clinical response could occur no
earlier than Visit 6 (Week 3) to ensure sufficient time
for patients to respond, and were made only at sched-
uled visits. Investigators were permitted to increase the
dose for LY2140023 patients to 160 mg/day (80 mg
BID), with no intermediate dose. Once patients reached
the target dose, dose adjustments for patients on compara-
tor medications could occur in the following increments:
olanzapine (+/− 5 mg/day), aripiprazole (+/− 10 mg/day),
or risperidone (+/− 2 mg/day).
Assessments
The primary objective of this study was to assess time to
discontinuation due to lack of tolerability, defined as dis-
continuation due to adverse events, among patients with
schizophrenia receiving LY2140023 versus those on
atypical antipsychotic SOC treatment for up to 24 weeks.
The classification of discontinuation due to adverse
events was based on the site investigator’s determination
that the primary reason for a patient's early withdrawal
from the study was an adverse event.
The secondary objectives of this study included evalu-
ation of the long-term safety, tolerability, and efficacy of
Table 1 Baseline and demographic characteristics
Characteristic LY2140023 SOC p Value*
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sessments included the incidence of treatment-emergent
adverse events (TEAEs), neurological changes, vital
signs, laboratory changes, and changes in electrocardio-
graphs and electroencephalographs (EEGs). Extrapyram-
idal symptoms were assessed by the Barnes Akathisia
Scale for akathisia [8], Simpson-Angus Scale for parkin-
sonism [9], and Abnormal Involuntary Movement Scale
for dyskinetic symptoms [10].
All patients had an EEG at baseline and at Weeks 2, 4,
8, 12, and 24 that were evaluated by a single central
neurologist. All EEGs were performed on the same
model device utilizing the same software and settings.
Efficacy was assessed by the PANSS [3], CGI-S [6], and
the 16-item Negative Symptoms Assessment (NSA-16)
scale [11]. Raters not directly involved with the patient’s
treatment were used to assess the PANSS and NSA-16
scales. The raters were blind to the study design, entrance
criteria, and treatment assignment; separate raters were
used for baseline and endpoint assessments.(N = 130) (N = 131)
Age, years, mean (SD) 38.7 (10.9) 39.5 (12.5) .579
Gender – female, n (%) 45 (34.6) 44 (33.6) .897
Race, n (%) - - .669
American Indian or Alaska
Native
20 (15.4) 18 (13.7) -
Black/African American 44 (33.8) 39 (29.8) -
Multiple 1 (0.8) 3 (2.3)
White 65 (50.0) 71 (54.2) -
Diagnosis, n (%) - - .202
Catatonic 1 (0.8) 0 (0.0) -
Disorganized 8 (6.2) 4 (3.1) -
Paranoid 100 (76.9) 109 (83.2) -
Residual 7 (5.4) 2 (1.5)
Undifferentiated 14 (10.8) 16 (12.2) -
Weight, kg, mean (SD) 83.0 (21.5) 82.7 (21.7) .907
Age of first episode, years,
mean (SD)
24.6 (8.3) 23.1 (8.5) .148
Episodes in the last 24 months,
mean (SD)
1.8 (1.6) 2.0 (2.1) .297
CGI-S, mean (SD) 3.8 (0.7) 3.7 (0.6) .943
PANSS total, mean (SD) 85.6 (14.8) 85.1 (15.8) .788
PANSS positive, mean (SD) 17.6 (4.7) 18.1 (4.8) .355
PANSS negative, mean (SD) 26.2 (4.9) 25.7 (5.2) .403
PANSS general psychopathology,
mean (SD)
41.9 (9.1) 41.4 (9.3) .644
Negative Assessment Scale-16,
mean (SD)
58.7 (11.0) 57.3 (11.3) .336
Abbreviations: CGI-S Clinical global impressions Severity, n/N Number of
patients, PANSS Positive and negative syndrome scale, SD Standard deviation.
Groups: LY2140023, LY2140023 monohydrate, SOC, Standard-of-care.
*P < .05, LY2140023 versus SOC.Statistical methods
All analyses were conducted on an intent-to-treat basis,
meaning that data were analyzed by the treatment
groups to which patients were randomly assigned, even
if the patient did not take the assigned treatment, did
not receive the correct treatment, or did not comply
with the protocol. No adjustments were made for multi-
plicity. All treatment comparisons were evaluated based
on a 2-sided significance level of 0.05.
Unless otherwise specified, when an analysis of vari-
ance (ANOVA) model or an analysis of covariance
(ANCOVA) model was used to analyze a continuous ef-
ficacy variable, the model contained the main effects of
treatment and investigator. Type III sum of squares for
the least-squares (LS) means were used for statistical
comparison from ANOVA or ANCOVA models.
For the analyses of change from baseline, only patients
with a baseline and at least 1 postbaseline measure were
included. Unless otherwise specified, baseline was de-
fined as the last nonmissing observation at or before the
randomization visit (Visit 3). Endpoint for Study Period
III (24 weeks) was defined as the last nonmissing obser-
vation obtained from Visit 4 through Visit 13.
The primary safety outcome was the time to discon-
tinuation due to adverse events during Study Period III.
Kaplan-Meier estimated survival curves [12] of time to
discontinuation (measured in days) for adverse events
were compared between LY2140023 and SOC. The log-
rank test was used to compare the LY2140023 and SOC
time-to-discontinuation profiles. This study was planned
to provide approximately 80% power to detect a hazard
ratio of 0.36 in the time to discontinuation due toadverse events over the 24-week active treatment phase
of the study.
Secondary efficacy outcomes for the PANSS total and
subscores were analyzed using the mixed-model re-
peated measures (analysis) model (MMRM), with the
fixed categorical effects of treatment, gender, investiga-
tor, visit, and treatment-by-visit interaction, as well as
the continuous, fixed covariate of baseline score and
baseline-by-visit interaction.
Results
Baseline and demographic characteristics
Patients in the 2 groups did not significantly differ with
respect to baseline characteristics (Table 1). More than
half of patients were male (65.9%) and white (52.1%).
Mean age was approximately 39 years (standard devi-
ation [SD] = 11.7). The mean PANSS total score was
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atology, and the mean PANSS negative score was greater
than the PANSS positive score, reflecting prominent
negative symptoms, as specified in the protocol.Dosing
The majority of LY2140023-treated patients were taking
the targeted dose (40 mg BID) at their final visit of the
Study Period (approximate incidence of patients in each
dose group at final visit: 14% patients at 20 mg BID; 62%
patients at 40 mg BID; and 25% patients at 80 mg BID).
The percentage of patients in the SOC group at their
final visit of the Study Period receiving the minimum
dose was 17%, the targeted dose was 46%, and the per-
centage receiving maximum dose was 38%. For each
drug subgroup within the SOC group, the percentage of
patients at their final visit of the study receiving the
minimum, targeted, and maximum doses were: OLZ,
20%, 36%, 44%; RIS, 16%, 60%, 24%; and ARI: 14%, 48%,
39%, respectively.Patient disposition
A total of 402 patients entered the study, and 261
patients were randomized to BID doses of LY2140023
(n = 130 patients) or SOC treatment (n = 131 patients);
27% of LY2140023 and 45% of SOC patients completed
through the final visit of Study Period III. The most
common reasons for study discontinuation among pa-
tients in both treatment groups were perceived lack of
efficacy, adverse events, and withdrawn consent. Twenty-
seven patients (20.8%) in the LY2140023 group and 15 pa-
tients (11.5%) in the SOC group discontinued due to lack
of efficacy (physician and subject decision combined;
P = .044). Twenty-three patients (17.7%) in the LY2140023


































Figure 2 Kaplan-Meier time to discontinuation due to adverse events
LY2140023 and SOC groups in time to discontinuation due to lack of toleradiscontinued due to adverse events (physician and subject
decision combined, P = .505).Primary objective – time to discontinuation due to
adverse events
There was no statistically significant difference between
the LY2140023 and SOC groups in time to discontinu-
ation due to lack of tolerability through 24 weeks (log-
rank test; P = .184; Figure 2).
However, time to discontinuation for any reason (p = .002)
was significantly shorter for patients in the LY2140023
group than for those on SOC (data not shown).Other safety measures
A total of 30 patients (LY2140023, n = 18; SOC, n = 12)
experienced at least 1 serious adverse event (SAE) dur-
ing the 24-week active-treatment phase of the study.
The incidence of SAEs was not significantly different be-
tween groups. Reported SAEs included 3 deaths: 2 were
in patients randomized to LY2140023, and 1 was in a pa-
tient who had not yet received any study drug. None of
the 3 deaths was considered by investigators to be re-
lated to treatment with study drug or to protocol
procedures.
One patient experienced 2 convulsions 1 day after dis-
continuing LY2140023 (approximately 3 weeks after
randomization) and initiating treatment with intramus-
cular haloperidol; the convulsions were reported as pos-
sibly related to LY2140023 treatment. Another patient
experienced a convulsion during the placebo lead-in
phase; this convulsion was reported as possibly related
to protocol procedure.
SAEs commonly reported (≥1% of LY2140023 patients)
in the LY2140023 group were schizophrenia, psychotic
disorder, agitation, insomnia, and pneumonia. Amongiscontinuation
LY2140023
SOC
. There was no statistically significant difference between the
bility through 24 weeks (log-rank test; P = .184).
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phrenia and psychotic disorder.
TEAEs reported at a statistically significantly higher rate
among LY2140023-treated patients than among those on
SOC included vomiting (P = .003), dyspepsia (P = .019),
and agitation (P = .011) (Table 2). Among patients in the
SOC group, akathisia (P = .019) and weight gain (P = .007)
were reported at a significantly greater rate compared with
the rate among those in the LY2140023 group.
Within-group comparisons revealed a significant reduc-
tion from baseline to last observation in fasting cholesterol
(−0.30 mmol/L, P < .001), LDL cholesterol (−0.28 mmol/L,
P < .001), and triglycerides (−0.11 mmol/L, P = .008) in pa-
tients treated with LY2140023, and a significant decrease
in HDL cholesterol (−0.06 mmol/L, P = .004) in patients
treated with SOC. There was a mean decrease in LDL
cholesterol in the LY2140023 group that was significantly
greater than the decrease observed in the SOC group
(P = .031), and a decrease in the level of triglycerides in
the LY2140023 group versus an increase in the SOC
group (P = .008). The mean decrease (−0.06 mmol/L) in
HDL cholesterol observed in the SOC group was signifi-
cantly different from the slight increase (0.01 mmol/L)
observed in the LY2140023 group (P = .018). A significant
reduction from baseline was also observed for prolactin
(−4.33 μg/L, P = .003) in the LY2140023 group, al-
though prolactin changes did not differ between the
groups (P = .062). There were no other clinicallyTable 2 Treatment-emergent adverse events at
incidence ≥5% in the LY2140023 group, or significantly
different between groups
Event, n (%) LY2140023 SOC P value
(N = 130) (N = 131)
Patients with ≥ TEAE 100 (76.9) 94 (71.8) .396
Insomnia 20 (15.4) 10 (7.6) .054
Anxiety 19 (14.6) 10 (7.6) .079
Headache 16 (12.3) 10 (7.6) .222
Vomiting 15 (11.5) 3 (2.3) .003*
Schizophrenia 12 (9.2) 11 (8.4) .831
Agitation 11 (8.5) 2 (1.5) .011*
Blood CPK increases 10 (7.7) 14 (10.7) .521
Nausea 10 (7.7) 4 (3.1) .108
Dyspepsia 8 (6.2) 1 (0.8) .019*
Nasopharyngitis 7 (5.4) 3 (2.3) .217
Akathisia 1 (0.8) 9 (6.9) .019*
Weight increased 0 (0.0) 8 (6.1) .007*
Abbreviations: CPK Creatinine phosphokinase, n/N Number of patients, SOC
Standard of care, TEAE Treatment-emergent adverse events.
Groups: LY2140023, LY2140023 monohydrate, SOC, Standard-of-care.
*P < .05, LY2140023 versus SOC. Events significantly different between
treatment groups are highlighted in bold text.significant differences in mean laboratory values between
treatment groups.
Within-group comparisons showed significant increases
in weight at every visit for patients in the SOC group
(maximum increase: 3.12 kg, P < .001), while LY2140023-
treated patients had significant decreases in weight at
Weeks 12, 16, and 24 (maximum decrease: -2.04 kg,
P < .05). Pairwise comparisons revealed significant differ-
ences in mean weight change between LY2140023- and
SOC-treated patients at every visit. Significantly more pa-
tients in the SOC group met potentially clinically significant
(PCS) criteria of an increase in weight of at least 7% from
baseline to endpoint (SOC, 21.4%, n = 28; LY2140023, 8.2%,
n = 10; P = .004), while significantly more patients in the
LY2140023 group met PCS criteria for decreased weight
(SOC, 2.3%, n = 3; LY2140023, 14.8%, n = 18; P < .001).
Within-group comparisons showed a mean reduction
from baseline in the Barnes Akathisia Scale global score for
akathisia at most visits in the LY2140023 group (P < .05),
while changes from baseline in the SOC group generally
did not reach significance. Both treatment groups had
statistically significant, within-group improvements on
the Simpson-Angus Scale total score for parkinsonism
at each visit (P < .001, most visits). There were few sta-
tistically significant differences observed from baseline
to postbaseline visit in the Abnormal Involuntary
Movement Scale total score for dyskinetic symptoms
within either treatment group. Pairwise comparisons
revealed few statistically significant differences between
the LY2140023 and SOC treatment groups across these
3 extrapyramidal symptom measures (data not shown).
The overall incidence of treatment-emergent parkin-
sonism (SOC, n = 14; LY2140023, n = 3; P = .011) and
akathisia (SOC, n = 18; LY2140023, n = 6; P = .029) was
significantly higher among patients treated with SOC
than among patients in the LY2140023 group.
Comparisons of changes in electrocardiogram intervals
and heart rate did not show significant differences be-
tween groups that were clinically significant.
There were no clinically significant differences in base-
line EEG scores between groups and no clinically signifi-
cant changes in postbaseline EEG scores. Abnormal
epileptiform-like changes were not frequent or remark-
ably different between treatment arms (LY2140023, 0%;
SOC, 3.4%).
Efficacy measures
Patients in both treatment groups demonstrated a statisti-
cally significant within-group mean reduction from base-
line in the PANSS total score at each visit (Figure 3A). A
similar mean reduction in the PANSS total score was
observed for patients in both groups from Weeks 1 to
6, while the improvement in psychopathology was sig-
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Figure 3 Efficacy measures. A. LS mean change from baseline to endpoint in PANSS total score in the LY2140023 and SOC treatment groups
estimated from the MMRM model; error bars indicate standard error. Mean PANSS total score at baseline (SD): LY2140023: 85.6 (14.8); SOC: 85.1
(15.8). For the PANSS Total Score, there was a significant effect of baseline (Overall MMRM, F [1,277] = 55.10, P < .001), and a significant effect of
treatment (Overall MMRM, F [1,173] = 4.20, P = .042). B. LS mean change from baseline to endpoint in NSA-16 total score in the LY2140023 and
SOC treatment groups estimated from the MMRM model; error bars indicate standard error. Mean NSA-16 total score at baseline (SD): LY2140023:
58.7(11.0); SOC: 57.3 (11.3). For the NSA-16 Total Score, there was a significant effect of baseline (Overall MMRM, F [1,207] = 36.55, P < .001), but
not a significant effect of treatment (Overall MMRM, F [1,180] = 0.39, P = .532). Abbreviations: LS = least squares; MMRM=mixed-model repeated
measures; NSA-16 = 16-item Negative Symptoms Assessment scale; PANSS = Positive and Negative Syndrome Scale; vs. = versus. Groups:
LY2140023 = LY2140023 monohydrate, SOC = standard-of-care. *P < .05, LY2140023 versus SOC.
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A similar response pattern as seen for the PANSS total
score was generally observed both within and between
the 2 treatment groups for the PANSS positive and gen-
eral psychopathology subscores, and for the CGI-S
(data not shown).
Patients in both treatment groups showed a statisti-
cally significant within-group mean reduction in the
PANSS negative subscore at all visits, with no significantdifferences observed between the LY2140023 and SOC
treatment groups (data not shown). Similarly, patients in
both treatment groups showed statistically significant
within-group mean improvement in the NSA-16 scale,
with no significant between-group differences (Figure 3B).
Medication compliance
Patient compliance with study medication was assessed
at each visit by direct questioning and by counting
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showed relatively high compliance rates with no between-
group differences (mean percentage study drug compli-
ance: SOC, 88%; LY2140023, 87%; P = .539).Concomitant medications
There were no statistically significant differences in the in-
cidence of concomitant use of any class of medication
(benzodiazepines/hypnotics/anxiolytics, antidepressants or
mood stabilizers, anticholinergic agents, or other therapies)
observed between the treatment groups during the active
treatment period. Approximately half of patients in this
study reported the use of at least 1 concomitant benzodi-
azepine anxiolytic, or hypnotic agent.Discussion
This study was a multicenter, randomized, open-label,
phase 2 clinical trial designed to evaluate the long-term
safety and tolerability of LY2140023 monohydrate
(LY2140023) in moderately ill patients with schizophre-
nia who had prominent negative symptoms and evidence
of functional impairment. The primary analysis showed
LY2140023 to be comparable to SOC in time to discon-
tinuation due to lack of tolerability through 24 weeks of
treatment. There were no significant differences between
treatment groups in the incidence of SAEs, TEAEs, or
adverse events leading to study discontinuation. How-
ever, a significantly greater number of patients in the
LY2140023 group discontinued from the study due to
perceived lack of efficacy compared with those in the
SOC group. In addition, time to discontinuation for any
reason was significantly shorter for patients in the
LY2140023 group than for those on SOC. All treatments
in the study were generally well-tolerated.
The safety findings from this 24-week study were gen-
erally consistent with observations from the 2 previous,
4-week clinical trials. In these acute trials, LY2140023-
treated patients generally did not differ significantly
from placebo-treated patients with regard to prolactin
elevation, extrapyramidal symptoms or weight gain,
while comparisons between placebo and olanzapine re-
vealed weight gain and limited or no reduction in pro-
lactin in the olanzapine-treated patients. In the current
study, LY2140023 treatment was characterized not only
by a decrease in mean weight over 24 weeks, as com-
pared with an increase observed with SOC treatment,
but also by improvement across various metabolic pa-
rameters. LY2140023 was associated with a reduction in
akathisia, and with less treatment-emergent akathisia
and parkinsonism as compared with SOC treatment.
This unique tolerability profile highlights possible advan-
tages of a glutamate-based schizophrenia therapy versus
dopaminergic-based therapies.The occurrence of convulsions within the 4-week
HBBI study identified a potentially increased risk of
seizures during treatment with LY2140023, warranting
further study following long-term exposure. In the current
study, there were 2 patients who experienced convulsive
events, 1 patient treated with LY2140023 and a second pa-
tient treated with placebo prior to randomization. The
overall LY2140023 exposure-adjusted rate of seizures had
decreased substantially with the increased compound ex-
posure in the current 24-week HBBR study and in other
ongoing studies. Extensive repeat EEG assessments did
not demonstrate any abnormal epileptiform-like changes
that were frequent nor remarkably different between treat-
ment arms. Study results do not suggest an increased risk
of seizures following long-term exposure. Based on results
of the current study, the safety profile of LY2140023 ap-
pears similar after short- and long-term exposure.
Efficacy was a secondary endpoint in this study. Im-
provement on the PANSS total score and most other
measures of efficacy over the initial 6 to 8 weeks of
treatment did not differ between treatments, while im-
provement at later time points was significantly greater
in the SOC group compared with LY2140023. The mean
PANSS visit response results were likely impacted by the
rate of early discontinuation and the treatment-group
difference in discontinuation due to lack of efficacy. A
post hoc analysis of only the patients who had PANSS
data at the last visit demonstrated similar improvement
in the SOC group and the LY2140023 group, although
there were significantly more patients with final visit
PANSS scores in the SOC group (data not shown).
LY2140023 and SOC had comparable negative symptom
improvement over the 24 weeks. Further investigation of
the efficacy of LY2140023 in the treatment of schizo-
phrenia utilizing placebo-controlled study is warranted.
Limitations
This study was an open-label study without a placebo
treatment arm, preventing definitive conclusions regard-
ing efficacy. This specific design element (that is, open-
label) was chosen in order to closely monitor the safety
of patients in this initial long-term study. In addition, in-
vestigators selected the SOC treatment to be used for
each patient in the SOC treatment group, and given the
knowledge available for these marketed drugs, SOC
treatment may have been optimized by clinicians to a
greater extent than for treatment with LY2140023. Nor-
mal EEGs were required at baseline, and therefore, any
safety results regarding seizures may be limited by this
less generalizable population. Similarly, this study fo-
cused on moderately ill patients with schizophrenia who
had prominent negative symptoms and evidence of func-
tional impairment, and therefore the data are primarily
generalizable to patients with a similar symptom profile.
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Conclusion
This was the first clinical study to examine the long-
term safety of a metabotropic glutamate receptor agon-
ist, a potential new therapeutic agent in the treatment of
schizophrenia. LY2140023 was comparable to atypical
SOC medications in the primary analysis of time-to-dis-
continuation due to adverse events, a finding demon-
strating that LY2140023 was generally well-tolerated
over clinically relevant treatment duration. Similar to
previous acute studies, LY2140023 had a distinct safety
profile characterized by a low incidence of dopamine-
related adverse events and a decrease in mean weight
compared with SOC treatment.
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